RECENT NEWS

NHS patients will be treated and cared for closer to their home by new teams of health professionals, as Prime Minister Keir Starmer revealed the long-awaited 10 Year Plan. The government describes the change as a “brand-new era for the NHS” promising to deliver one of the most seismic shifts in care in the history of the health service.

The pioneering Yellow Card Biobank, launched by the Medicines and Healthcare products Regulatory Agency (MHRA) and Genomics England, is investigating whether the risk of acute pancreatitis from GLP-1 injections for weight loss and type 2 diabetes may be influenced by a person’s genes.

Cell biologists have made a significant advance, uncovering the key role of an enzyme in determining the physical structure and behaviour of cancer cells, including how they spread.

The Institute of Biomedical Science (IBMS) has welcomed the publication of the new Industrial Strategy and its focus on life sciences.

The Medicines and Healthcare products Regulatory Agency (MHRA) has published its Business Plan for 2025–26, the final year covered by its 2023-2026 Corporate Plan.

Digital pathology and AI firm PathAI has announced that it has received 510(k) clearance from the US Food and Drug Administration (FDA) for AISight Dx - its digital pathology image management system - for use in primary diagnosis in clinical settings.

The MHRA will help shape international rules for AI in healthcare – speeding up access to safe, effective technologies into the NHS and worldwide, after the UK became one of the first countries in the world to join a new global network of health regulators.

Clinical scientist Ian Godber stepped into the role of President of the Association for Laboratory Medicine (LabMed), at LabMedUK25 in Manchester on 11 June 2025, officially succeeding Kath Hayden. The Association also unveiled a new five-year strategy at the event.

PathPresenter, an image management system and workflow platform for digital pathology, has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the PathPresenter Clinical Viewer for the purpose of primary diagnosis.

Diagnostics firm bioMérieux has announced an agreement to acquire the assets of Day Zero Diagnostics, a US-based infectious disease diagnostics company using genome sequencing and machine learning to combat the rise of antibiotic-resistant infections.

Upfront Diagnostics has launched a pioneering clinical study in Puerto Rico to evaluate its novel stroke blood test, LVOne.

A new study from a University of Minnesota research team has demonstrated that measuring SARS-CoV-2 in wastewater continues to accurately predict COVID-19 infections in a community.

A new research paper further underscores the relevance of RFLP-based genotyping as an affordable substitute for next-generation sequencing for early prostate cancer detection, in light of limited accessibility in many resource-limited settings.

Genomics England’s 2025 Research Summit recently welcomed a captivated audience to hear about the latest research and technological innovations from Genomics England, participants, its esteemed research community and members of the wider genomic research and healthcare community.

Aiforia Technologies has launched a new CE-IVD marked clinical AI solution for breast cancer grading.

The Medicines and Healthcare products Regulatory Agency (MHRA) has opened a second round of applications to its AI Airlock programme following a successful pilot phase.

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has launched its refreshed strategic direction, with new CEO Lawrence Tallon saying the agency will focus on safety, accelerated access and innovation as it looks to become a global leader in risk-proportionate regulation.

The College of American Pathologists (CAP) is to launch a new virtual artificial intelligence (AI) platform to give pathologists experience with digital technology.

Greater diversity is needed in genetic research to make genomics’ use in cancer care and screening more accurate and reliable for all, according to a new study.

From 16 June 2025, a landmark reform of how medical devices are regulated in Great Britain takes effect, as part of a Medicines and Healthcare products Regulatory Agency (MHRA) broader transformation of the UK’s medical device regulatory framework.